Telomir Pharmaceuticals, Inc. — Form 8-K Summary
Reporting date: February 8, 2024; the offering subsequently closed on February 13, 2024. The filing reports a material equity financing and related Nasdaq listing disclosures. Telomir is incorporated in Florida and trades under TELO on the Nasdaq Capital Market.
Offering and Key Financial Terms
- The company issued and sold 1,000,000 shares of common stock at $7.00 per share.
- Gross proceeds were $7.0 million, before underwriting discounts, commissions, and other estimated offering expenses.
- The underwriting discount was 7% of gross proceeds; the filing does not provide a clear final net-proceeds amount.
- The underwriter received warrants to purchase 50,000 shares at an exercise price of $7.00 per share.
- The representative warrants become exercisable six months after February 8, 2024 and remain exercisable for four and one-half years thereafter, subject to the terms described in the warrant.
- The underwriter received a 45-day option to purchase up to an additional 150,000 shares.
Material Changes and Market Activity
- The financing increased the company’s common-stock capitalization and may dilute existing stockholders.
- Telomir’s common stock began trading on Nasdaq under the symbol TELO on February 9, 2024.
- The offering closed on February 13, 2024, after the February 8 pricing and underwriting agreement.
- Officers, directors, and certain stockholders agreed to lock-up restrictions generally lasting 180 days, or 365 days for initial holders, subject to exceptions and underwriter consent.
Liquidity, Outlook, and Risks
The offering provides additional capital, but the filing does not state the company’s cash balance, cash-burn rate, debt, revenue, profitability, operating cash flow, or intended allocation of proceeds. Net proceeds are reduced by the underwriting discount and other offering expenses, and the filing text does not provide a clear final amount.
- Exercise of the representative warrants or the underwriter’s additional-share option could create further dilution.
- The offering agreement includes customary representations, warranties, covenants, and indemnification obligations.
- The filing does not provide new operating guidance, financial forecasts, or management commentary regarding business performance.
- Lock-up restrictions may limit near-term share sales, but future sales after expiration could affect the stock price.
Investor Verification Items
- Verify the final net proceeds after the 7% underwriting discount and all offering expenses.
- Review the underwriting agreement and representative warrant for exercise, adjustment, and resale provisions.
- Determine whether the 45-day over-allotment option was exercised and quantify any resulting dilution.
- Review subsequent filings for use of proceeds, cash runway, operating losses, and additional financing needs.
- Confirm the total post-offering shares outstanding and the potential dilution from all warrants and options.